8-K: Vivos Therapeutics Faces Nasdaq Delisting Threat Despite Prior Compliance

Vivos Therapeutics has received a delisting notice from Nasdaq due to falling below the minimum stockholders' equity requirement, despite previously demonstrating compliance.

Summary

• Vivos Therapeutics was previously notified by Nasdaq that they had regained compliance with the minimum stockholders' equity requirement of $2.5 million.
• This compliance was based on capital raising activities completed in November 2023 and February 2024.
• However, on May 16, 2024, Nasdaq issued a new notice stating that Vivos Therapeutics had failed to maintain the minimum stockholders' equity requirement as of the date of the notice.
• This determination was based on the company's stockholders' equity reported in its Quarterly Report on Form 10-Q for the period ended March 31, 2024, which was less than $2.5 million.
• Nasdaq has commenced delisting proceedings against the company.
• Vivos Therapeutics has appealed the decision and requested an additional hearing, which has temporarily stayed the delisting process.
• The company's stock will remain listed on Nasdaq pending the outcome of the hearing.
• Vivos Therapeutics is currently working to regain compliance with the minimum stockholders' equity requirement.
• There is a risk that the company will be unable to demonstrate compliance, and there is no guarantee that the Hearing Panel will agree with the company's assessment of compliance.
• Delisting from Nasdaq would have a material adverse effect on the company's stock price, the ability of its stockholders to trade their shares, the company's ability to raise capital, and its reputation.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. The company's stock price and reputation are at risk.

Positives

• Vivos Therapeutics has appealed the delisting notice and requested an additional hearing.
• The appeal has temporarily stayed the delisting process, allowing the company's stock to remain listed on Nasdaq pending the outcome of the hearing.
• The company is actively working to regain compliance with the minimum stockholders' equity requirement.

Negatives

• Vivos Therapeutics has received a delisting notice from Nasdaq due to failing to meet the minimum stockholders' equity requirement.
• The company's stockholders' equity was less than $2.5 million as of March 31, 2024.
• There is a risk that the company will be unable to demonstrate compliance and that the Hearing Panel will not agree with the company's assessment of compliance.
• Delisting from Nasdaq would have a material adverse effect on the company.

Risks

• There is a risk that Vivos Therapeutics will be unable to demonstrate ongoing compliance with the minimum stockholders' equity requirement.
• The Hearing Panel may not agree with the company's assessment of compliance.
• Delisting from Nasdaq would have a material adverse effect on the company's stock price, the ability of its stockholders to trade their shares, the company's ability to raise capital, and its reputation.
• The company's ability to operate could be significantly more difficult if delisted.

Future Outlook

The company is undertaking efforts to regain and evidence continuing compliance with the Minimum Stockholders Equity Requirement, but there is no assurance that they will be successful. The company's stock will remain listed on Nasdaq pending the outcome of the hearing.

Management Comments

• The company is presently undertaking efforts to regain and evidence continuing compliance with the Minimum Stockholders Equity Requirement.
• The company has appealed the Nasdaq staff's determination and requested an additional hearing.

Industry Context

This announcement highlights the challenges faced by smaller companies in maintaining listing requirements on major exchanges like Nasdaq, particularly in volatile market conditions. It underscores the importance of consistent financial performance and adequate capitalization for continued listing.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance, especially those that are pre-revenue or have fluctuating financial performance.
• Companies like Aytu BioPharma and Diffusion Pharmaceuticals have also faced delisting threats due to similar issues with minimum equity requirements.
• The $2.5 million minimum equity requirement is a standard benchmark for Nasdaq Capital Market listings, and failure to meet this threshold is a common reason for delisting notices.

Stakeholder Impact

• Shareholders face the risk of a significant decrease in the value of their investment if the company is delisted.
• The company's ability to raise capital may be severely impacted if delisted.
• The company's reputation could be damaged by the delisting process.

Next Steps

• Vivos Therapeutics will participate in a hearing with the Nasdaq Hearing Panel to appeal the delisting notice.
• The company will continue to work to regain and evidence compliance with the minimum stockholders' equity requirement.
• The company will report any progress or consummation of efforts to the Hearings Panel.

Key Dates

Keywords

delisting, Nasdaq, stockholders' equity, compliance, hearing, capital raising, Vivos Therapeutics, minimum equity, appeal